cerca CERCA
Mercoledì 21 Aprile 2021
Aggiornato: 06:15
Temi caldi

CHIMICA E FARMACEUTICA

Scholle IPN Acquires Flexible Packaging Equipment Company, Bossar

NORTHLAKE, Ill., March 11, 2021 /PRNewswire/ -- Scholle IPN, a leading global supplier of flexible packaging solutions, announced today that they have completed the purchase of Bossar, a global supplier of flexible horizontal form-fill-seal packaging equipment.

Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients

TAICHUNG, March 10, 2021 /PRNewswire/ -- Alar Pharmaceuticals Inc. (TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces positive interim results from the single-ascending-dose study of ALA-1000. A 3-month buprenorphine released injectable designed to be dosed subcutaneously for treating opioid use disorder (OUD).

Precision Toxicology consortium aims to protect human health from effects of harmful chemicals

BRUSSELS, March 9, 2021 /PRNewswire/ -- A major research project to shape regulation and policy on chemical safety without the use of animal testing has been launched with the aid of €19.3M funding from the European Commission under H2020 program. Led by the University of Birmingham and involving 15 European and US organisations, PrecisionTox aims to protect human health from the toxic effects of chemicals found in people's homes, food and the environment. The Precision Toxicology consortium will...

Winhealth Pharma and Merz Collaborate on Hepa-Merz® to benefit patients with liver disease in China

HANG ZHOU, China, March 9, 2021 /PRNewswire/ -- On Feb. 26th, 2021, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as "Winhealth Pharma") signed a strategic cooperation agreement with Merz Pharmaceuticals GmbH (hereinafter referred to as "Merz"). The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz® (L-ornithine L-aspartate, an important product under Merz' product portfolio) in China.

Polyplastics Expands DURACON (R) POM PM Series with New High-flow Grade for Medical and Healthcare Industry

TOKYO, Feb. 25, 2021 /PRNewswire/ -- The Polyplastics Group is expanding its DURACON (R) polyoxymethylene (POM) PM series portfolio with the development of a new high-flow grade for drug contact and delivery applications for the medical and healthcare market. The new grade, DURACON PM27S01N, offers reduced wall thickness, miniaturization, and lower weight for various medical devices that are becoming increasingly complicated and highly functional.

icometrix expands icobrain portfolio with ischemic stroke solution

LEUVEN, Belgium and BOSTON, Feb. 23, 2021 /PRNewswire/ -- icometrix, world leader in imaging AI solutions for people with neurological conditions, announced the addition of icobrain cva, a stroke solution, to the icobrain portfolio. The announcement follows the FDA-clearance and CE-marking of its image processing software for the analysis and communication of the tissue perfusion state on computer tomography (CT) perfusion scans in patients with ischemic stroke. icobrain cva provides physicians w...

Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A

LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ -- Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www.thieme-connect.com/products/ejournals/abstra...

Willow Biosciences Announces Exercise of Over-Allotment Option and Completion of Previously Announced Bought Deal Offering

VANCOUVER, BC, Feb. 19, 2021 /PRNewswire/ -- Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (TSX: WLLW.WT) (OTCQX: CANSF) is pleased to announce that it has closed its previously announced upsized bought deal offering of 17,424,800 common shares (the "Common Shares") of the Company at a price of $1.65 per Common Share, which includes 2,272,800 Common Shares issued pursuant to the exercise in full of the over-allotment option, for aggregate gross proceeds of approximately $28.75 m...

Gerresheimer presents strong fourth quarter

DÜSSELDORF, Germany, Feb. 18, 2021 /PRNewswire/ -- Gerresheimer AG posted strong growth in the fourth quarter of 2020 and landed inside the target range despite the negative impact of the COVID-19 pandemic. "Business in the fourth quarter was very strong. It was the best quarter in the Company's history. Despite the negative impact of the coronavirus pandemic, especially in our cosmetics business, we reached our goals for 2020. The successful acceleration of growth in large parts of our core busi...

Noma Medical Crisis: le leggende del calcio africano lanciano un appello per le donazioni per salvare i "bambini senza volto"

PARIGI, 16 febbraio 2021 /PRNewswire/ -- Sebbene ogni anno colpisca più di 140.000 bambini, il noma rimane una malattia pressochè sconosciuta per il grande pubblico. Derivata dal greco "nomein", che significa "divorare", la malattia distrugge il viso, causando la morte del bambino nel 90% dei casi. Per combattere questo flagello, nel 2019, l'ex calciatore Roger Milla ha fondato l'associazione Noma Fund. Insieme a ex giocatori internazionali come Joseph-Antoine Bell, François Omam-Biyik, Patrick M...

Medicom Healthcare Ltd announces the signing of an Asset Purchase Agreement of BIMATOPROST 0.3 mg/mL, 3ml

LONDON, Feb. 10, 2021 /PRNewswire/ -- Medicom Healthcare Limited (Medicom) and Famar Health Care Services Madrid (Famar) are pleased to announce the signing of an Asset Purchase Agreement (APA) for the acquisition by Medicom of the pharmaceutical dossier of BIMATOPROST 0.3 mg/mL, 3ml, preservative free eye drop solution, developed by Famar R&D. Under this agreement, Medicom has acquired the ownership of the product dossier which is already registered in the UK and 5 EU countries with plans to com...

ora in
Prima pagina
Tag più usati
in questa pagina

change in emea region

executive

leadership

leadership change

partner di canale

prodotti imdsoft

servizi metavision

sistema informativo

articoli
in Evidenza